Lataa...
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted th...
Tallennettuna:
| Julkaisussa: | J Clin Med |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7563273/ https://ncbi.nlm.nih.gov/pubmed/32932888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092934 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|